I thought this was a typo a week or two ago when I saw mention of the latest Rituxan trial for PPMS being a Phase III trial, but this exerpt from a press release today says it again, so I guess it's not a typo.
Genentech Announces Full Year and Fourth Quarter 2005 Results
Tuesday January 10, 4:29 pm ET
Record Annual Revenues of $6.6 Billion Drive Year-Over-Year Non-GAAP EPS Growth of 54 Percent
SOUTH SAN FRANCISCO, Calif., Jan. 10 /PRNewswire-FirstCall/
In the fourth quarter of 2005, Genentech completed enrollment in the Phase III study of Rituxan in primary progressive multiple sclerosis
, as well as in the Phase II combination study of Avastin and Tarceva in non-small cell lung cancer.